Objective:

To discuss the advancements and current status of CAR-T therapies and bispecific antibodies in the treatment of hematologic malignancies.

Approach:

• Research Compilation: The editorial compiles original research, systematic reviews, and clinical case reports to elucidate the current status of CAR-T therapies and bispecific antibodies.
• Meta-Analysis: He et al. conducted a meta-analysis comparing CAR-T therapy and bispecific antibodies in relapsed/refractory follicular lymphoma.
• Benefit-Risk Analysis: Wang et al. synthesized data from 59 trials to compare efficacy and safety of CD19/CD22 dual-targeted CAR-T therapy and CD3×CD20 bispecific antibodies.
• Case Reports: Various case reports explored the application of these therapies in real-world populations, including patients with pre-existing conditions.
• Toxicity Management: Akiyama et al. documented a case of autologous stem cell boost for severe cytopenia due to bispecific antibody therapy.
• Sequential Modalities: Oura et al. presented a case of epcoritamab's effectiveness in neurolymphomatosis, suggesting BsAbs as a bridging strategy.
• Diagnostic Precision: Ibraheem and Dalby emphasized the importance of differentiating cytokine release syndrome from sepsis in CAR-T therapy management.
• Comprehensive Review: Amirmokhtari and Lutfi reviewed trials that led to FDA approvals and investigated resistance mechanisms.

Key Findings:

• CAR-T therapy showed higher complete response rates (82% vs. 65%) compared to bispecific antibodies in relapsed/refractory follicular lymphoma.
• CD19/CD22 dual-targeted CAR-T therapy was found to be in a more favorable efficacy-safety zone than CD3×CD20 bispecific antibodies.
• CAR-T therapy can be safely administered to patients with pre-existing conditions with appropriate monitoring and support.
• Sequential use of bispecific antibodies may stabilize patients before CAR-T therapy.

Interpretation:

The editorial discusses the roles of CAR-T therapies and bispecific antibodies in treating hematologic cancers, highlighting the importance of patient selection and toxicity management.

Limitations:

• The rapid integration of these therapies into clinical practice has outpaced the ability to compare their efficacy and manage toxicity.
• Real-world data may not fully represent the outcomes seen in clinical trials.

Conclusion:

The editorial indicates that CAR-T therapies and bispecific antibodies should be viewed as complementary treatment options.